Invega Phase IV examines lower doses
Executive Summary
Johnson & Johnson will seek to identify a minimal effective dose for Invega (paliperidone extended-release) during post-marketing studies; a study protocol is due to FDA by April. Data supporting approval for the schizophrenia agent suggest the lower end of the dose-response curve has not been fully evaluated, according to the agency's Dec. 19 approval letter (1"The Pink Sheet" Jan. 1, 2007, p. 5). J&J plans to market Invega with the sales force that currently markets the atypical antipsychotic Risperdal (risperidone), without adding reps. The product, a metabolite of Risperdal, has begun shipping...
You may also be interested in...
Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.